Physician profile
Barbara Ann Dehn
NPI 1841438983
$87,477.23
in general payments reported to CMS, 2019-2025
22 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $5,154 · 2023: $10K · 2024: $18K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Travel and Lodging: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,381 · Food and Beverage: $3,183 · Honoraria: $2,300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,952.50 |
| Travel and Lodging | $14,862.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,380.53 |
| Food and Beverage | $3,183.24 |
| Honoraria | $2,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,261.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47,772.68 | 2023-2025 | |
| Acella Pharmaceuticals, LLC | $12,361.09 | 2023-2025 | NP Thyroid 60 |
| Gen-Probe, INC. | $9,449.55 | 2021 | |
| Pfizer INC. | $6,000.00 | 2021-2023 | |
| Shield Therapeutics INC | $4,497.47 | 2023 | Accrufer |
| Scynexis, INC. | $1,964.82 | 2022 | |
| Gen-Probe Sales & Service, INC. | $1,449.35 | 2021 | |
| Exact Sciences Corporation | $949.69 | 2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $900.00 | 2022 | |
| Sumitomo Pharma America, INC. | $437.87 | 2023-2025 | Myfembree, Gemtesa |
| Lupin INC. | $396.00 | 2021 | |
| Therapeuticsmd, INC. | $260.79 | 2021-2022 | |
| Astellas Pharma US INC | $250.00 | 2023 | Veozah |
| Astellas Pharma Global Development | $231.02 | 2023-2025 | Veozah |
| Novo Nordisk INC | $130.51 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $121.82 | 2023 | Andexxa |
| Exeltis, USA INC. | $58.58 | 2024 | |
| Myovant Sciences INC. | $45.51 | 2022 | |
| Hologic Sales and Service, LLC | $30.15 | 2021 | |
| Biogen, INC. | $28.80 | 2023 | |
| Agile Therapeutics, INC. | $16.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Dehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.